Search results
Results from the WOW.Com Content Network
Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). [4] [5] The medication improves sexual desire, increases the number of satisfying sexual events, and decreases the distress associated with low sexual desire. [6]
About Compounded Tirzepatide. Compounded tirzepatide is a formulation of tirzepatide — a medication for type 2 diabetes and weight loss. Tirzepatide is the active ingredient in the FDA-approved ...
Melanotan II acts as a non-selective agonist of the melanocortin receptors MC 1, MC 3, MC 4, and MC 5. [5]Melanotan II produces melanogenesis by activation of the MC 1 receptor, whereas its clinically documented sexual effects are thought to be related to its ability to activate the MC 4 receptor (though the MC 3 is thought to also possibly be involved).
Eflornithine, sold under the brand name Vaniqa among others, is a medication used to treat African trypanosomiasis (sleeping sickness) and excessive hair growth on the face in women. [ 1 ] [ 3 ] [ 4 ] Specifically it is used for the second stage of sleeping sickness caused by T. b. gambiense and may be used with nifurtimox .
A New Drug Application of bremelanotide for female sexual dysfunction was accepted by the US Food and Drug Administration (FDA) in June 2018, with a Prescription Drug User Fee Act (PDUFA) goal date set for 23 March 2019. [30] It was approved for use in the United States in June 2019. [3] [31] [32]
The U.S. Food and Drug Administration is considering a ban on certain hair-straightening chemicals that have been used by Black women for years and that research shows may increase the risk of ...
This is a complete list of estrogens and formulations that are approved by the FDA Tooltip Food and Drug Administration and available in the United States. Estrogens are used as hormonal contraceptives , in hormone replacement therapy , and in the treatment of gynecological disorders .
NuvaRing was first approved in The Netherlands in February 2001, then by the European Union in June 2001, and in the United States by the US Food and Drug Administration (FDA) in October 2001. [39] [40] NuvaRing was first marketed in the United States in July 2002, [41] followed by a number European countries since then. [42]